SCYNEXIS Future Growth

Future criteria checks 0/6

SCYNEXIS's revenue and earnings are forecast to decline at 13% and 23.3% per annum respectively while EPS is expected to decline by 25.2% per annum.

Key information

-23.3%

Earnings growth rate

-25.2%

EPS growth rate

Pharmaceuticals earnings growth21.4%
Revenue growth rate-13.0%
Future return on equityn/a
Analyst coverage

Low

Last updated31 Jan 2024

Recent future growth updates

Recent updates

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Feb 01
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Dec 21
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Apr 13
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Mar 15
Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks Like

Feb 01
Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks Like

Cantor initiates with Overweight rating for Scynexis and Ardelyx on potential drug approval

Jan 06

Trade Alert: The CEO, President & Director Of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Has Just Spent US$250k Buying 57% More Shares

Dec 28
Trade Alert: The CEO, President & Director Of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Has Just Spent US$250k Buying 57% More Shares

Scynexis shares drop after pricing its equity offering

Dec 17

SCYNEXIS, Inc. (NASDAQ:SCYX): Are Analysts Optimistic?

Dec 15
SCYNEXIS, Inc. (NASDAQ:SCYX): Are Analysts Optimistic?

Earnings and Revenue Growth Forecasts

NasdaqGM:SCYX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261116423335
12/31/202590381121185
12/31/20247125N/A555
12/31/202314284N/A784
9/30/2023136724545N/A
6/30/2023136441010N/A
3/31/20236-91-83-83N/A
12/31/20225-63-80-80N/A
9/30/20224-78-83-83N/A
6/30/20223-49-78-77N/A
3/31/20222-34-71-70N/A
12/31/202113-33-56-55N/A
9/30/202113-46-46-46N/A
6/30/202112-45-39-39N/A
3/31/202112-53-36-36N/A
12/31/2020N/A-55-49-49N/A
9/30/2020N/A-27-46-46N/A
6/30/2020N/A-36-47-47N/A
3/31/20200-38-46-46N/A
12/31/20190-54-38-38N/A
9/30/20190-37-31-31N/A
6/30/20190-29-27-26N/A
3/31/20190-31-27-27N/A
12/31/20180-12-29-28N/A
9/30/20180-22-28-27N/A
6/30/20180-31-27-27N/A
3/31/20180-24-26-26N/A
12/31/20170-25-25-25N/A
9/30/20170-21-24-24N/A
6/30/20170-24N/A-26N/A
3/31/20170-28N/A-27N/A
12/31/20160-30N/A-29N/A
9/30/20160-35N/A-31N/A
6/30/20160-31N/A-30N/A
3/31/20160-30N/A-29N/A
12/31/20150-28N/A-25N/A
9/30/20151-23N/A-20N/A
6/30/20151-19N/A-18N/A
3/31/20151-11N/A-14N/A
12/31/20141-7N/A-9N/A
9/30/20144-42N/A-9N/A
6/30/20148-43N/A-6N/A
3/31/201412-47N/A-2N/A
12/31/201317-47N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SCYX's earnings are forecast to decline over the next 3 years (-23.3% per year).

Earnings vs Market: SCYX's earnings are forecast to decline over the next 3 years (-23.3% per year).

High Growth Earnings: SCYX's earnings are forecast to decline over the next 3 years.

Revenue vs Market: SCYX's revenue is expected to decline over the next 3 years (-13% per year).

High Growth Revenue: SCYX's revenue is forecast to decline over the next 3 years (-13% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SCYX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.